We Are Focused on the Rapid Clinical and Commercial Development of New Medicines Based on Our Exceptional 3D Human Tissue Model Technology.
Organovo creates human models of inflammatory bowel disease (IBD) using our 3D tissue technologies and uses them to understand, invent, and develop the best drug therapies for ulcerative colitis and Crohn’s disease. We believe that drugs discovered through this method have a greater chance to show benefit in clinical trials.
FXR314, is Organovo’s lead therapeutic molecule. FXR314 demonstrated benefit to ulcerative colitis in Organovo’s models of disease as well as extensive preclinical testing. It has shown, in initial clinical trials, to be a possible best-in-class FXR agonist that is delivered orally, with high potency, safety, tolerability and the potential to avoid dose-limiting toxicity issues found in other FXR targeted compounds. FXR314 has received FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis. Organovo also plans to investigate FXR314 for the treatment of other Inflammatory Bowel Diseases including Crohn’s Disease as well as diseases of the Liver including non-alcoholic steatohepatitis (NASH) and Primary Biliary Cholangitis. Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science.
We are pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic key aspects of human biology and disease. We intend to fundamentally alter the drug discovery landscape by the development of novel therapies for disease which have a much higher chance of efficacy in the clinic focused on human primary cell 3D models of disease that more faithfully recapitulate disease processes.